CMPX Filings — Compass Therapeutics, Inc. - FilingSpy
CMPX
Compass Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing antibody-based therapies for cancer and autoimmune disease, working on programs such as bispecific antibodies and antibody-drug conjugates. It grew out of Boston's biotech ecosystem, founded by drug-development scientists in the early 2010s to build a pipeline of novel antibody medicines aimed at solid tumors. The company takes its name from the guiding idea of using antibodies to "point" the immune system, like a compass, toward cancer cells — a naming quirk that frames its whole mission.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +5.45M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.